BioIntel is now The Catalyst Brief.
The Catalyst Brief
Coverage

Biopharmaceutical Industry

Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.

Page 9 of 30

Archive

Akeso Reports Phase 3 Ivonescimab Survival Win In Biliary Tract Cancer, Extending Its Case Beyond Lung CancerAug 27, 2026

Akeso Reports Phase 3 Ivonescimab Survival Win In Biliary Tract Cancer, Extending Its Case Beyond Lung Cancer

Akeso described the Harmoni-GI1 result as clinically meaningful and statistically significant on overall survival, with progression-free survival and objective response rate also met. Strategically, the readout broadens the drug’s tumor-type story at a time when debate over changing progression-free survival magnitudes in lung cancer has sharpened attention on what kind of evidence regulators may ultimately value most.

The Catalyst Brief
Revolution Medicines Wins FDA Approval For Rasonque In Metastatic Pancreatic Adenocarcinoma, Months Ahead Of DeadlineAug 26, 2026

Revolution Medicines Wins FDA Approval For Rasonque In Metastatic Pancreatic Adenocarcinoma, Months Ahead Of Deadline

Rasonque was cleared for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The approval arrived more than half a year before the Prescription Drug User Fee Act deadline after a review that included the FDA’s Commissioner’s National Priority Voucher program.

The Catalyst Brief
Lilly Launches Foundayo In The U.K., Extending The Oral Obesity Race Beyond The U.S.Aug 25, 2026

Lilly Launches Foundayo In The U.K., Extending The Oral Obesity Race Beyond The U.S.

Foundayo is approved in the U.K. for adults with obesity or who are overweight and have at least one weight-related comorbidity, and it is also indicated for type 2 diabetes. Analysts cited by BioSpace said Lilly may be better positioned outside the U.S. because Foundayo is a small-molecule drug, potentially supporting better margins and more pricing flexibility than a peptide rival.

The Catalyst Brief
Spruce Aligns With FDA On TA-ERT Filing, Setting Up Q4 MPS IIIB SubmissionAug 24, 2026

Spruce Aligns With FDA On TA-ERT Filing, Setting Up Q4 MPS IIIB Submission

TA-ERT could become the first FDA-approved therapy for MPS IIIB if Spruce reaches the regulator on its revised timeline. The latest update matters less as a clinical surprise than as a manufacturing de-risking step for a program whose data were viewed as more settled than its CMC path.

The Catalyst Brief
Neumora Reshuffles Leadership Ahead Of NLRP3 IND And Phase 1 ReadoutsAug 23, 2026

Neumora Reshuffles Leadership Ahead Of NLRP3 IND And Phase 1 Readouts

Neumora is reorganizing its top team as it approaches a cluster of near-term development events. The timing matters because the company is trying to advance an NLRP3 inhibitor into the clinic for obesity while also generating early data in Alzheimer’s disease and schizophrenia.

The Catalyst Brief
Boehringer Ingelheim Suspends BI 3031185 Phase 1 Study, After An Undisclosed Safety Event In JapanAug 22, 2026

Boehringer Ingelheim Suspends BI 3031185 Phase 1 Study, After An Undisclosed Safety Event In Japan

The hold interrupts an early clinical program that had only started in early July and that included healthy male and healthy female participants in separate parts of the study. For investors and peers, the immediate signal is less about a single asset than about how little visibility companies sometimes provide when a first-in-human or early-stage safety review begins.

The Catalyst Brief
Ultragenyx Wins Genglycos Approval In GSDIa, Opening Its First Gene Therapy LaunchAug 22, 2026

Ultragenyx Wins Genglycos Approval In GSDIa, Opening Its First Gene Therapy Launch

The approval covers adults and children age 8 and older with glycogen storage disease type Ia and positions Genglycos as an adjunct to nutritional management that can reduce daily cornstarch intake. For Ultragenyx, the decision is both a product launch and a platform validation point after years of investment in gene therapy.

The Catalyst Brief
Regeneron Wins Pasatru Approval In FOP, Opening A Second U.S. Drug Market Against IpsenAug 21, 2026

Regeneron Wins Pasatru Approval In FOP, Opening A Second U.S. Drug Market Against Ipsen

The approval covers Pasatru, also known as garetosmab and REGN2477 during development, to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. The launch changes the structure of a market that had only one approved drug, with Mirum Pharmaceuticals also approaching an FDA decision on zilurgisertib by Sept. 26.

The Catalyst Brief

Other beats

AI in Drug Discovery

Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.

Biotech Innovation

Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.

Healthcare Investment

Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.

Medical Technology

Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.

Regulatory & Policy

FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.